A Phase 2 interventional study of PM01183 in Breast Cancer, sponsored by PharmaMar. Completed at 9 sites in 2 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-25.
Sponsored by PharmaMar · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast Cancer (MBC) patients, to evaluate the safety profile of this PM01183 to analyze the pharmacokinetics (PK) and PK/PD (pharmacokinetic/pharmacodynamic) correlations and to evaluate the pharmacogenomic (PGx) expression profile in tumor samples.
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer to assess the antitumor activity of PM01183 in terms of overall response rate (ORR), duration of response (DR),clinical benefit [ORR or stable disease lasting over three months (SD > 3 months)], progression free survival (PFS), and one-year overall survival (1y-OS) and to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in MBC patients, to explore the activity of PM01183 in specific breast cancer subpopulations according to hormonal receptor status, HER-2 overexpression, number and/or type of prior therapies, or according to other available histological/molecular classifications, to evaluate the safety profile of this PM01183 administration schedule [Day 1 every three weeks (q3wk)] in this patient population, to analyze the pharmacokinetics (PK) of PM01183 in this patient population, to explore PK/PD (pharmacokinetic/ pharmacodynamic) correlations, if applicable and to evaluate the pharmacogenomic (PGx) expression profile of selected putative markers potentially predictive of response to PM01183, in tissues from tumor samples.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
This study's enrollment of 111 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least three weeks since the last chemotherapy (six weeks in some particular cases) and At least four weeks since the last radiotherapy (RT) > 30 Gy) and At least one week since the last hormonal therapy and At least two weeks since the last biological/ therapy
Exclusion Criteria:
History of cardiac disease. Moderate breathing difficulties or oxygen requirement Active uncontrolled infection. Unhealed wound or presence of any external drainage. Chronically active viral hepatitis. patients, including those known to be infected by (HIV).
Known muscular disease or functional alteration
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PM01183
PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
Overall Response Rate (ORR)
The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR \>=30% decrease in the sum of the longest diameter of target lesions.
Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Overall Response
Overall Response Rate (ORR) in the population evaluable for efficacy according to RECIST v.1.1. ORR was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions; SD, stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; TF, treatment failure.
Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Duration of Response
Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.
Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Duration of Response Rate at 6 Months
Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.
Time frame: Time between the response criteria date and the date when disease progression, recurrence or death was documented, up to 6 months
Duration of Response Rate at 12 Months
Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.
Time frame: Time between the response criteria date and the date when disease progression, recurrence or death was documented, up to 12 months
Clinical Benefit Rate
Clinical benefit, defined as the percentage of patients with ORR or SD lasting over three months (SD \>3 months). The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR \>=30% decrease in the sum of the longest diameter of target lesions. SD, stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Progression-free Survival (PFS)
Progression-free survival (PFS) is defined as the period of time from the date of first infusion to the date of progression disease, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: 36 months
Progression-free Survival at 3 Months
Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 3 months
Progression-free Survival at 6 Months
Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 6 months
Progression-free Survival at 12 Months
Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 12 months
Overall Survival (OS)
Overall survival (OS) will be defined as time from the date of first infusion to the date of death or last contact
Time frame: 36 months
Overall Survival Rate at 12 Months
Overall survival (OS), defined as the time from the date of first infusion to the date of death or last contact
Time frame: Time from the date of first infusion to the date of death or last contact, up to 12 months
Overall Survival Rate at 18 Months
Overall survival (OS), defined as the time from the date of first infusion to the date of death or last contact.
Time frame: Time from the date of first infusion to the date of death or last contact, up to 18 months
The first patient was included on 27JUN12 and the first study treatment administration was on 28JUN12. The cutoff date for the results was 24OCT18. A total of 111 patients were included in the 3 cohorts of the study: 56 in Cohort A (BRCA+), 20 in Cohort A1 (BRCA+/PARPi), 35 in Cohort B (Unselected).
| Milestone | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Started | 56 | 20 | 35 |
| Completed | 0 | 0 | 0 |
| Not completed | 56 | 20 | 35 |
| Withdrew: Non-treatment-related ae | 1 | 0 | 0 |
| Withdrew: Progressive disease | 48 | 15 | 29 |
| Withdrew: Never treated | 2 | 0 | 0 |
| Withdrew: Physician decision | 4 | 2 | 2 |
| Withdrew: Death | 0 | 0 | 2 |
| Withdrew: Treatment-related ae | 1 | 1 | 2 |
| Withdrew: Other reasons | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR \>=30% decrease in the sum of the longest diameter of target lesions.
| percentage | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Overall Response Rate (ORR) | 40.7 (27.6 to 55.0) | 5.0 (0.1 to 24.9) | 8.8 (1.9 to 23.7) |
Overall Response Rate (ORR) in the population evaluable for efficacy according to RECIST v.1.1. ORR was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions; SD, stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; TF, treatment failure.
| Participants | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| CR | 2 | 0 | 0 |
| PR | 20 | 1 | 3 |
| SD | 24 | 9 | 17 |
| PD | 8 | 10 | 13 |
| TF | 0 | 0 | 1 |
Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.
| months | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Duration of Response | 6.3 (3.4 to 12.7) | 2.7 (NA to NA) | 3.6 (2.1 to 16.1) |
Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.
| percentage of participants | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Duration of Response Rate at 6 Months | 53.1 (31.8 to 74.4) | 0 (NA to NA) | 33.3 (0 to 86.7) |
Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.
| percentage of participants | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Duration of Response Rate at 12 Months | 33.8 (13.5 to 54.1) | 0 (NA to NA) | 33.3 (0 to 86.7) |
Clinical benefit, defined as the percentage of patients with ORR or SD lasting over three months (SD \>3 months). The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR \>=30% decrease in the sum of the longest diameter of target lesions. SD, stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| percentage of participants | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Clinical Benefit Rate | 61.1 (46.9 to 74.1) | 40.0 (19.1 to 63.9) | 32.4 (17.4 to 50.5) |
Progression-free survival (PFS) is defined as the period of time from the date of first infusion to the date of progression disease, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| months | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Progression-free Survival (PFS) | 4.6 (3.0 to 6.2) | 1.4 (1.3 to 3.9) | 2.5 (1.3 to 3.4) |
Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| percentage of participants | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Progression-free Survival at 3 Months | 63.5 (50.4 to 76.6) | 42.5 (20.3 to 64.7) | 35.5 (18.9 to 52.1) |
Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| percentage of participants | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Progression-free Survival at 6 Months | 37.6 (24.2 to 50.9) | 21.3 (2.8 to 39.7) | 11.1 (0 to 22.6) |
Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| percentage of participants | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Progression-free Survival at 12 Months | 20.5 (9.1 to 31.9) | 0 (0 to 0) | 3.7 (0 to 10.7) |
Overall survival (OS) will be defined as time from the date of first infusion to the date of death or last contact
| months | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Overall Survival (OS) | 18.6 (10.9 to 22.8) | 8.1 (4.6 to 14.6) | 12.1 (6.6 to 17.9) |
Overall survival (OS), defined as the time from the date of first infusion to the date of death or last contact
| percentage of participants | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Overall Survival Rate at 12 Months | 62.5 (49.0 to 75.9) | 29.7 (7.9 to 51.5) | 55.4 (37.9 to 73.0) |
Overall survival (OS), defined as the time from the date of first infusion to the date of death or last contact.
| percentage of participants | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Overall Survival Rate at 18 Months | 53.4 (39.2 to 67.5) | 22.3 (1.6 to 42.9) | 27.7 (11.5 to 43.9) |
Collected over Participants were assessed through study completion, aproximately 6 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A (BRCA+) | 40/54 (74.1%) | 14/54 (25.9%) | 54/54 (100%) |
| Cohort A1 (BRCA+/PARPi) | 13/20 (65%) | 5/20 (25%) | 20/20 (100%) |
| Cohort B (Unselected) | 30/35 (85.7%) | 8/35 (22.9%) | 34/35 (97.1%) |
| Event | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 7/54 | 2/20 | 0/35 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/54 | 0/20 | 0/35 |
| VomitingGastrointestinal disorders | 3/54 | 0/20 | 0/35 |
| Staphylococcal bacteraemiaInfections and infestations | 0/54 | 1/20 | 0/35 |
| FallInjury, poisoning and procedural complications | 0/54 | 1/20 | 0/35 |
| Platelet count decreasedInvestigations | 1/54 | 1/20 | 0/35 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/54 | 1/20 | 0/35 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/54 | 1/20 | 0/35 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/54 | 1/20 | 0/35 |
| SyncopeNervous system disorders | 0/54 | 1/20 | 0/35 |
| Event | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) |
|---|---|---|---|
| fatigueGeneral disorders | 48/54 | 10/20 | 30/35 |
| nauseaGastrointestinal disorders | 43/54 | 15/20 | 20/35 |
| neutropeniaBlood and lymphatic system disorders | 24/54 | 11/20 | 7/35 |
| NeutropeniaInvestigations | 24/54 | 11/20 | 7/35 |
| constipationGastrointestinal disorders | 23/54 | 9/20 | 9/35 |
| vomitingGastrointestinal disorders | 23/54 | 7/20 | 10/35 |
| Decreased appetiteMetabolism and nutrition disorders | 15/54 | 6/20 | 5/35 |
| HeadacheNervous system disorders | 16/54 | 6/20 | 5/35 |
| diarrhoeaGastrointestinal disorders | 16/54 | 4/20 | 5/35 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/54 | 2/20 | 6/35 |
| Age, Categorical(Participants) | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 51 | 19 | 30 | 100 |
| >=65 years | 5 | 1 | 5 | 11 |
| Age, Continuous(years) | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) | Total |
|---|---|---|---|---|
| Median | 42.5 (30 to 73) | 45.0 (31 to 66) | 52.0 (32 to 70) | 45.0 (30 to 73) |
| Sex: Female, Male(Participants) | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) | Total |
|---|---|---|---|---|
| Female | 56 | 20 | 35 | 111 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) | Total |
|---|---|---|---|---|
| Race — Caucasian | 50 | 16 | 32 | 98 |
| Race — Black | 2 | 0 | 1 | 3 |
| Race — Asian | 1 | 1 | 0 | 2 |
| Race — Hispanic | 2 | 1 | 2 | 5 |
| Race — Unknown | 1 | 2 | 0 | 3 |
| Region of Enrollment(participants) | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) | Total |
|---|---|---|---|---|
| United States | 35 | 16 | 9 | 60 |
| Spain | 21 | 4 | 26 | 51 |
| ECOG PS(Participants) | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) | Total |
|---|---|---|---|---|
| PS 0 | 32 | 10 | 22 | 64 |
| PS 1 | 24 | 10 | 13 | 47 |
| Sites of disease at diagnosis(Participants) | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) | Total |
|---|---|---|---|---|
| Left breast | 26 | 11 | 18 | 55 |
| Right breast | 28 | 9 | 15 | 52 |
| Bilateral | 2 | 0 | 2 | 4 |
| Histology type at diagnosis(Participants) | Cohort A (BRCA+) | Cohort A1 (BRCA+/PARPi) | Cohort B (Unselected) | Total |
|---|---|---|---|---|
| Ductal carcinoma | 54 | 20 | 34 | 108 |
| Lobular carcinoma | 2 | 0 | 0 | 2 |
| Lobular and ductal carcinoma | 0 | 0 | 1 | 1 |
15 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2012 to primary completion in Oct 2018, 76 months.
Results were first posted in Sep 2020, 1 year 11 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 76 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PM 01183